193 related articles for article (PubMed ID: 9168003)
1. Quantifying estrogen metabolism: an evaluation of the reproducibility and validity of enzyme immunoassays for 2-hydroxyestrone and 16alpha-hydroxyestrone in urine.
Ziegler RG; Rossi SC; Fears TR; Bradlow HL; Adlercreutz H; Sepkovic D; Kiuru P; Wahala K; Vaught JB; Donaldson JL; Falk RT; Fillmore CM; Siiteri PK; Hoover RN; Gail MH
Environ Health Perspect; 1997 Apr; 105 Suppl 3(Suppl 3):607-14. PubMed ID: 9168003
[TBL] [Abstract][Full Text] [Related]
2. A new ELISA kit for measuring urinary 2-hydroxyestrone, 16alpha-hydroxyestrone, and their ratio: reproducibility, validity, and assay performance after freeze-thaw cycling and preservation by boric acid.
Falk RT; Rossi SC; Fears TR; Sepkovic DW; Migella A; Adlercreutz H; Donaldson J; Bradlow HL; Ziegler RG
Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):81-7. PubMed ID: 10667467
[TBL] [Abstract][Full Text] [Related]
3. Menstrual cycle effects on urinary estrogen metabolites.
Xu X; Duncan AM; Merz-Demlow BE; Phipps WR; Kurzer MS
J Clin Endocrinol Metab; 1999 Nov; 84(11):3914-8. PubMed ID: 10566628
[TBL] [Abstract][Full Text] [Related]
4. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women.
Muti P; Bradlow HL; Micheli A; Krogh V; Freudenheim JL; Schünemann HJ; Stanulla M; Yang J; Sepkovic DW; Trevisan M; Berrino F
Epidemiology; 2000 Nov; 11(6):635-40. PubMed ID: 11055622
[TBL] [Abstract][Full Text] [Related]
5. The ratio of the estradiol metabolites 2-hydroxyestrone (2-OHE1) and 16α-hydroxyestrone (16-OHE1) may predict breast cancer risk in postmenopausal but not in premenopausal women: two case-control studies.
Ruan X; Seeger H; Wallwiener D; Huober J; Mueck AO
Arch Gynecol Obstet; 2015 May; 291(5):1141-6. PubMed ID: 25318606
[TBL] [Abstract][Full Text] [Related]
6. Increased urinary excretion of 2-hydroxyestrone but not 16alpha-hydroxyestrone in premenopausal women during a soya diet containing isoflavones.
Lu LJ; Cree M; Josyula S; Nagamani M; Grady JJ; Anderson KE
Cancer Res; 2000 Mar; 60(5):1299-305. PubMed ID: 10728690
[TBL] [Abstract][Full Text] [Related]
7. The 2-/16α-Hydroxylated Estrogen Ratio-Breast Cancer Risk Hypothesis: Insufficient Evidence for its Support.
Stanczyk FZ
J Steroid Biochem Mol Biol; 2020 Jul; 201():105685. PubMed ID: 32320758
[TBL] [Abstract][Full Text] [Related]
8. Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and family history of breast cancer in premenopausal women.
Ursin G; London S; Yang D; Tseng CC; Pike MC; Bernstein L; Stanczyk FZ; Gentzschein E
Breast Cancer Res Treat; 2002 Mar; 72(2):139-43. PubMed ID: 12038704
[TBL] [Abstract][Full Text] [Related]
9. Epidemiologic studies of estrogen metabolism and breast cancer.
Ziegler RG; Fuhrman BJ; Moore SC; Matthews CE
Steroids; 2015 Jul; 99(Pt A):67-75. PubMed ID: 25725255
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibody-based enzyme immunoassay for simultaneous quantitation of 2- and 16 alpha-hydroxyestrone in urine.
Klug TL; Bradlow HL; Sepkovic DW
Steroids; 1994 Nov; 59(11):648-55. PubMed ID: 7701541
[TBL] [Abstract][Full Text] [Related]
11. Measurement of urinary estrogen metabolites using a monoclonal enzyme-linked immunoassay kit: assay performance and feasibility for epidemiological studies.
Chen C; Malone KE; Prunty J; Daling JR
Cancer Epidemiol Biomarkers Prev; 1996 Sep; 5(9):727-32. PubMed ID: 8877065
[TBL] [Abstract][Full Text] [Related]
12. Reproducibility of plasma and urinary sex hormone levels in premenopausal women over a one-year period.
Michaud DS; Manson JE; Spiegelman D; Barbieri RL; Sepkovic DW; Bradlow HL; Hankinson SE
Cancer Epidemiol Biomarkers Prev; 1999 Dec; 8(12):1059-64. PubMed ID: 10613337
[TBL] [Abstract][Full Text] [Related]
13. A pilot study of urinary estrogen metabolites (16alpha-OHE1 and 2-OHE1) in postmenopausal women with and without breast cancer.
Ursin G; London S; Stanczyk FZ; Gentzschein E; Paganini-Hill A; Ross RK; Pike MC
Environ Health Perspect; 1997 Apr; 105 Suppl 3(Suppl 3):601-5. PubMed ID: 9168002
[TBL] [Abstract][Full Text] [Related]
14. Comparison of liquid chromatography-tandem mass spectrometry, RIA, and ELISA methods for measurement of urinary estrogens.
Faupel-Badger JM; Fuhrman BJ; Xu X; Falk RT; Keefer LK; Veenstra TD; Hoover RN; Ziegler RG
Cancer Epidemiol Biomarkers Prev; 2010 Jan; 19(1):292-300. PubMed ID: 20056650
[TBL] [Abstract][Full Text] [Related]
15. Estrogen metabolism and risk of breast cancer in postmenopausal women.
Fuhrman BJ; Schairer C; Gail MH; Boyd-Morin J; Xu X; Sue LY; Buys SS; Isaacs C; Keefer LK; Veenstra TD; Berg CD; Hoover RN; Ziegler RG
J Natl Cancer Inst; 2012 Feb; 104(4):326-39. PubMed ID: 22232133
[TBL] [Abstract][Full Text] [Related]
16. Urinary markers of estrogen metabolism 2- and 16 alpha-hydroxylation in premenopausal women.
Pasagian-Macaulay A; Meilahn EN; Bradlow HL; Sepkovic DW; Buhari AM; Simkin-Silverman L; Wing RR; Kuller LH
Steroids; 1996 Aug; 61(8):461-7. PubMed ID: 8870165
[TBL] [Abstract][Full Text] [Related]
17. Circulating estrogen metabolites and risk for breast cancer in premenopausal women.
Arslan AA; Shore RE; Afanasyeva Y; Koenig KL; Toniolo P; Zeleniuch-Jacquotte A
Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2273-9. PubMed ID: 19661086
[TBL] [Abstract][Full Text] [Related]
18. Within-person variability of the ratios of urinary 2-hydroxyestrone to 16alpha-hydroxyestrone in Caucasian women.
Chen Z; Zheng W; Dunning LM; Anderson KG; Parrish RS; Holtzman JL
Steroids; 1999 Dec; 64(12):856-9. PubMed ID: 10576221
[TBL] [Abstract][Full Text] [Related]
19. Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women.
Ursin G; London S; Stanczyk FZ; Gentzschein E; Paganini-Hill A; Ross RK; Pike MC
J Natl Cancer Inst; 1999 Jun; 91(12):1067-72. PubMed ID: 10379970
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled, cross-over trial to evaluate the effect of EstroSense
Green T; See J; Schauch M; Reil J; Glover M; Brix J; Gerry A; Li K; Newman M; Gahler RJ; Wood S
J Complement Integr Med; 2023 Mar; 20(1):199-206. PubMed ID: 36201753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
